Table 5.
Baseline characteristics, DSS relevant parameters and outcome variables in control + RRT patients and CytoSorb-treated individuals. Presented are mean values ± standard deviations, frequency and percentage (%) and levels of significance.
| Control + RRT Group (n = 69) | CytoSorb Group (n = 198) | p-Value | |
|---|---|---|---|
| Age (years) | 66.2 (±12.4) | 62.3 (±14.9) | 0.035 |
| APACHE II (points) | 39.8 (±9.6) | 33.8 (±10.0) | <0.001 |
| SAPS II (points) | 56.2 (±14.8) | 59.5 (±17.6) | 0.144 |
| Ventilator days | 12.3 (±13.4) | 13.0 (±18.2) | 0.715 |
| ICU stay (days) | 19.9 (±18.1) | 19.5 (±23.5) | 0.882 |
| Hospital stay (days) | 30.2 (±28.9) | 28.7 (±37.9) | 0.703 |
| ICU mortality (%) | 44 (63.8%) | 118 (59.6%) | 0.540 |
| Hospital mortality (%) | 49 (71.0%) | 123 (63.6%) | 0.268 |
| Lactate T0 (mmol/L) | 4.96 (±4.28) | 4.76 (±3.63) | 0.738 |
| Lactate T6 (mmol/L) | 5.08 (±4.40) | 4.73 (±3.52) | 0.565 |
| Norepinephrine T0 (µg/kg/min) | 0.37 (±0.41) | 0.46 (±0.48) | 0.142 |
| Norepinephrine T6 (µg/kg/min) | 0.55 (±0.44) | 0.57 (±0.41) | 0.783 |
| Second catecholamine T0 (%) | 17 (24.6%) | 111 (56.1%) | <0.001 |
| Hydrocortisone T0 (%) | 37 (53.6%) | 136 (68.7%) | 0.024 |
| Volume bolus used (mL/kg) | 75.6 (±30.0) | 78.0 (±27.6) | 0.537 |
| Dynamic Scoring System (points) | 7.20 (±1.68) | 7.80 (±1.82) | 0.014 |